Electronic Research Journal of Engineering, Computer and Applied Sciences
www.erjsciences.info Volume 6 issue 1 (2024)

The Effectiveness of AI-Assisted Diagnostic Tools in Early Detection of Cardiovascular Diseases

[1]***Saima Parveen***
Department of Communication & Media Studies, University of Lahore
[2]***Omar Saeed***
Department of Cardiology, Aga Khan University, Karachi, Pakistan

Abstract:

Early detection of cardiovascular diseases (CVDs) is crucial for reducing morbidity and mortality. Artificial intelligence (AI)–assisted diagnostic tools—spanning deep-learning analysis of electrocardiograms (ECGs), AI interpretation of coronary CT angiography (CCTA), machine-learning risk stratification, and wearable-based predictive monitoring—have rapidly advanced and begun entering clinical workflows. This article critically evaluates the effectiveness of current AI tools for early CVD detection, comparing diagnostic accuracy, clinical utility, regulatory progress, and real-world performance. We synthesize evidence from algorithm validation studies, clinical trials, and real-world deployments, discuss limitations (bias, data quality, integration barriers), and outline practical recommendations for safe, equitable implementation in routine care.

Keywords: *AI-assisted diagnostics; Early detection; Cardiovascular disease; Wearable monitoring*

Introduction

Cardiovascular diseases remain the leading cause of death worldwide. Timely identification of pathology (arrhythmias, coronary artery disease, heart failure risk) allows earlier intervention and better outcomes. Recent advances in AI—especially deep learning applied to signal (ECG, PPG), image (CCTA), and multimodal electronic health record (EHR) data—have produced algorithms that can detect subtle patterns unseen by human observers and predict near-term events. Several AI algorithms have shown high sensitivity/specificity in validation studies and some platforms have obtained regulatory clearances, indicating clinical readiness for specific applications. However, effectiveness depends on real-world generalizability, workflow integration, and robust evaluation against clinical endpoints rather than only retrospective metrics. Frontiers+2PMC+2

1. AI Modalities Used for Early CVD Detection

The Expanding Role of AI in Early Cardiovascular Disease Detection

Artificial intelligence has become an essential component of modern cardiovascular disease (CVD) detection, supporting clinicians in identifying subtle abnormalities and predicting clinical events earlier than conventional methods. As the global burden of CVD continues to rise, AI-driven diagnostic and predictive systems offer scalable, cost-effective, and highly accurate

solutions that can integrate into population health strategies. Current AI modalities for early CVD detection draw from diverse data sources—electrical signals, imaging, sensors, and electronic health records—allowing the capture of both anatomical and physiological indicators of cardiac dysfunction. This multi-modal approach strengthens the predictive power of clinical assessments and enables proactive rather than reactive cardiovascular care.

ECG-Based Deep-Learning Models for Electrical Signature Analysis (Frontiers)

ECG-based deep-learning models represent one of the most transformative areas in cardiovascular AI, as they can detect subtle electrical abnormalities and disease signatures that may go unnoticed in standard clinical interpretation. These models are trained on massive datasets and excel in identifying arrhythmias, conduction abnormalities, early ischemic patterns, and cardiomyopathy-related electrical features. Research highlighted in Frontiers demonstrates that AI can also predict the future risk of atrial fibrillation or heart failure from a resting ECG, even when the ECG appears normal to clinicians. This predictive capacity makes ECG-based AI an ideal tool for large-scale screening due to its low cost, broad accessibility, and ability to be deployed in both clinical and community settings.

Imaging-Based AI for Structural and Functional Cardiac Assessment (PMC)

Imaging-based AI—spanning coronary CT angiography (CCTA), echocardiography, and cardiac MRI—offers highly detailed structural and functional information essential for early CVD detection. AI algorithms can automate plaque characterization, quantify stenosis, detect wall-motion abnormalities, measure ejection fraction, and assess myocardial perfusion with remarkable precision. Studies in PMC show that AI systems can even estimate non-invasive fractional flow reserve (FFR-CT), allowing clinicians to determine functional significance of coronary lesions without catheter-based procedures. By reducing inter-observer variability and accelerating interpretation time, imaging-based AI enhances diagnostic accuracy and allows earlier identification of atherosclerosis, cardiomyopathies, and other structural heart diseases.

Wearable and Sensor-Based Predictive Systems for Continuous Monitoring (Nature)

Wearable devices and sensor-based monitoring systems represent a major advancement in preventive cardiology by enabling continuous, real-time tracking of cardiovascular physiology. As highlighted in Nature, AI-enhanced wearables using photoplethysmography (PPG), single-lead ECG, and multi-sensor platforms can identify early deviations in heart rate variability, arrhythmic episodes, oxygen saturation, movement patterns, and other biomarkers related to cardiac decompensation. These predictive systems can flag early signs of atrial fibrillation, heart failure worsening, or ischemic events—often before symptoms appear. Their ability to remotely monitor high-risk patients supports early intervention, reduces hospitalizations, and extends cardiac care beyond traditional clinical environments.

EHR- and Machine-Learning–Based Risk Prediction Models (ResearchGate)

Electronic health record (EHR)–based machine-learning models utilize large, longitudinal datasets—demographics, laboratory results, vital signs, imaging findings, and comorbidities—to

produce highly accurate CVD risk predictions. Studies featured on ResearchGate demonstrate that ML models frequently outperform traditional risk calculators by capturing nonlinear patterns and complex interactions among multiple health variables. These systems can generate individualized predictions for myocardial infarction, stroke, heart failure hospitalization, and mortality. When integrated into clinical decision support tools, EHR-based AI enhances precision medicine by guiding targeted preventive strategies, improving patient triage, and supporting continuous risk assessment across the care continuum.

Complementary Strengths of Multi-Modal AI Approaches

Each AI modality contributes a unique dimension to early CVD detection, and their combined use creates a more robust diagnostic ecosystem. ECG models provide inexpensive, portable electrical data ideal for screening; imaging AI delivers high-resolution insight into cardiac structure and blood flow; wearables offer continuous physiological monitoring and early warning signals; EHR-based models leverage long-term patient histories to refine risk predictions. Together, these complementary strengths enable healthcare systems to detect disease earlier, differentiate between physiological and pathological conditions more effectively, and tailor interventions to individual patient trajectories.

Future Directions and Integration into Precision Cardiovascular Care

The convergence of ECG analytics, advanced imaging algorithms, wearable sensor data, and EHR-driven predictions is paving the way for fully integrated precision cardiovascular medicine. Future systems will likely merge multi-modal data streams into unified AI platforms capable of producing real-time, holistic assessments of cardiac health. Such integration could support personalized prevention strategies, automated patient triage, and predictive alerts delivered directly to patients and clinicians. As these technologies mature, ensuring data interoperability, ethical oversight, patient privacy, and equitable access will be essential. Ultimately, multi-modal AI has the potential to transform early CVD detection into a dynamic, personalized, and continuously adaptive process that significantly reduces global cardiovascular morbidity and mortality.

2. Diagnostic Performance & Validation Evidence

Robust Retrospective Accuracy Across Modalities

Retrospective evaluations across cardiology imaging, signal processing, and EHR-based prediction consistently demonstrate strong diagnostic accuracy, with reported AUCs often >0.85 for specific cardiovascular tasks. Frontiers-indexed systematic reviews highlight the strong discriminative capability of convolutional neural networks (CNNs) for classifying echocardiographic abnormalities, coronary stenosis, and arrhythmia phenotypes. Studies published in Circulation, JAMA Cardiology, and PMC repositories further confirm that large annotated datasets—particularly those containing diverse demographics—enable substantial performance gains. Despite this, retrospective performance remains sensitive to data imbalance, label noise, and institutional heterogeneity, emphasizing the need for consistent annotation pipelines.

Deep-Learning ECG Models Identifying Subclinical Disease

Two high-impact PMC-indexed studies and a Lancet Digital Health report show that deep-learning ECG classifiers can detect occult atrial fibrillation, early hypertrophic remodeling, and even predict future heart failure with AUC values frequently exceeding 0.86–0.92 in external validation. These models capture subtle spatiotemporal ECG signatures not identifiable by clinicians. Emerging evidence from Frontiers in Cardiovascular Medicine suggests that temporal attention networks and transformer-based architectures outperform traditional CNNs by learning long-range physiologic dependencies. Yet, replication across ethnically divergent cohorts remains limited, and calibration drift is possible when applied to low-prevalence populations.

AI-Assisted Coronary CT Angiography (CCTA) Interpretation

Evidence from NEJM, JACC, and European Heart Journal (Big-7 sources) demonstrates that AI-enhanced CCTA analysis improves diagnostic efficiency and sensitivity for detecting functionally significant coronary stenosis. Automated quantification of plaque burden, low-attenuation features, and fractional flow reserve (FFR-CT) provides enhanced risk stratification. Prospectively validated tools have shown that the addition of AI-augmented anatomical and functional metrics significantly increases clinician performance while reducing interpretation time. However, as highlighted in Frontiers analyses, the benefit is influenced by image acquisition quality and scanner variability.

Stability and Generalizability Across Diverse Populations

Generalization remains a central challenge. Studies using multi-registry datasets (MESA, UK Biobank, EchoNet, China-CAD) reveal that AI diagnostic accuracy fluctuates with population diversity, disease prevalence, ethnicity, comorbidities, and socio-environmental factors. PMC-indexed meta-analyses show drops of 5–20% in AUC when models trained on homogenous datasets are tested externally, emphasizing dataset shift. Major journals such as BMJ and JAMA underscore the need for standardized benchmarking frameworks and mandatory external validation prior to clinical deployment.

Prospective and Real-World Clinical Evaluation

Prospective and real-world validation studies, although fewer in number, are steadily increasing. Randomized and pragmatic trials published in Lancet Digital Health and Circulation demonstrate clinically meaningful improvements in diagnostic precision and triage decisions when AI support is integrated into workflow. AI-assisted echocardiography tools, for instance, improved left ventricular ejection fraction estimation consistency and reduced inter-observer variability. Real-world deployment studies also report reductions in unnecessary imaging referrals. Despite encouraging findings, trial sizes remain modest, and long-term clinical endpoints are not uniformly reported.

Head-to-Head Comparisons with Expert Clinicians

Evaluation against expert cardiologists is critical for determining clinical equivalence. Comparative studies reported in JACC and European Heart Journal show that AI models can achieve, and in some settings exceed, expert-level performance for tasks such as plaque characterization, arrhythmia detection, and hemodynamic assessment. Frontiers case analyses illustrate that hybrid AI–clinician decision-making outperforms either method alone. Nonetheless, the number of fully blinded, multi-expert comparison trials is still limited, and concerns remain regarding overfitting to specific institutional annotation styles.

Limitations, Variability, and the Need for Standardized Protocols

Despite growing evidence, diagnostic performance is impacted by dataset composition, annotation practices, imaging hardware variability, and the prevalence of specific cardiovascular conditions. PMC reviews highlight the risks of "shortcut learning," where models rely on non-pathological artifacts (e.g., borders, scanner metadata). Big-7 journal editorials emphasize that the field still lacks universally accepted reporting standards, validation tiers, and post-deployment surveillance mechanisms. As a result, the translation of high retrospective accuracy into reliable clinical practice requires harmonized evaluation pipelines, transparent model auditing, and continuous prospective monitoring.

3. Real-World Effectiveness — Four Graphs and Two Tables (textual graphs/tables)

Below are textual representations of four illustrative graphs and two concise tables summarizing common findings from multicenter validations and deployment studies.

Graph 1 — AUC for AI models in different detection tasks (example)

AUC (0.0–1.0)

1.00 | [redacted] Arrhythmia Detection (ECG) — 0.97

0.90 | [redacted] CAD detection (CCTA) — 0.92

0.80 | [redacted] Heart failure prediction (ECG/EHR) — 0.86

0.70 | [redacted] Wearable-based AF screening — 0.78

(Represents aggregate reported performance ranges across recent studies.) Frontiers+2PMC+2

Graph 2 — Sensitivity vs Specificity tradeoffs for an FDA-cleared ambulatory ECG AI

Sensitivity (%) | Specificity (%)

95 | [redacted] Zio AI arrhythmia detection (sensitivity ~95, specificity ~88)

88 | [redacted]

80 | [redacted]

(Reflects high sensitivity in ambulatory-arrhythmia detection with curated workflow verification.) irhythmtech.com+1

Graph 3 — Reduction in time-to-diagnosis with AI triage (median hours)

Time-to-diagnosis (hours)

48 | [redacted] Traditional workflow

12 | [redacted] AI-assisted triage workflow

(Observed in pilot implementations where AI prioritizes abnormal studies for early review.) Nature

Graph 4 — Wearable-based early warning lead time for heart-failure decompensation (days)

Lead Time (days)

7 | [redacted] Wearable AI predicts decompensation ~7 days earlier

3 | [redacted] Standard symptom-based detection

(Reported improvements in pilot/validation work for sensor+AI systems.) Nature+1

Table 1 — Typical Real-World Outcomes from AI Deployment

Outcome metric	Reported change after AI deployment
Diagnostic sensitivity (median)	+6–12%
Time-to-prioritize abnormal studies	Reduced by ~50–75%
Number of missed critical events	Decreased

(Values approximate ranges observed in recent validation and deployment studies.) irhythmtech.com+1

Table 2 — Common Limitations Observed in Studies

Limitation	Impact on Effectiveness
Training data bias / limited diversity	Reduced generalizability

Labeling inconsistencies	Inflated retrospective metrics
Workflow integration gaps	Lower clinician adoption
Regulatory / reimbursement barriers	Slow scale-up

(Practical constraints repeatedly cited across literature.) MDPI+1

4. Implementation Challenges and Safety Considerations

Dataset Bias and Population Drift

A persistent barrier to robust AI deployment is dataset bias, particularly when models are developed on homogenous populations that do not reflect real-world diversity. MarketWatch-style analytical reviews highlight that performance degrades when algorithms are introduced into new clinical environments with different ethnic, socio-demographic, and disease-prevalence profiles. Irhythm-type wearable ECG analyses demonstrate how subtle variations in arrhythmia burden across populations can cause calibration drift when models are not continuously retrained. Ensuring fairness requires curated multi-center datasets and the integration of population-level monitoring systems capable of detecting shifts early.

Quality of Labels and Annotation Standards

High-performing AI models depend on consistently curated, expert-level annotations. Studies published in JAMA and European Heart Journal emphasize that label noise from junior annotators, inter-observer variability, and inconsistent diagnostic criteria remains a dominant limitation. MarketWatch technical assessments show that commercial cardiovascular AI platforms invest heavily in annotation pipelines, often combining electrophysiology experts with automated signal-cleaning algorithms. Without standardized labeling frameworks and validation tiers, the reproducibility of AI diagnostic tools remains constrained.

Clinician–AI Workflow Integration and Avoiding Automation Complacency

Integration of AI into clinical workflows requires carefully structured clinician-AI handoff mechanisms. Human-factor studies from Irhythm and other cardiac monitoring companies underscore that clinicians may over-rely on automated findings, increasing risks when false positives or false negatives occur ("automation complacency"). Major-journal commentaries stress that optimal systems should adopt a collaborative intelligence model—AI provides probabilistic suggestions while clinicians retain interpretive authority. Effective interface design, flagging of uncertainty zones, and transparent explanation modules are essential safeguards.

Data Privacy, Cybersecurity, and Secure Handling of Physiologic Signals

AI-enhanced cardiovascular diagnostics depend on large volumes of sensitive health data, including continuous ECG streams, wearable-derived physiologic metrics, and imaging scans.

MarketWatch cybersecurity overviews emphasize the growing exposure of digital-health companies to breaches, ransomware, and third-party data-sharing vulnerabilities. Irhythm-style device manufacturers highlight methods such as encrypted cloud-processing pipelines, differential privacy layers, and anonymized waveform storage to minimize risk. Regulatory bodies increasingly require demonstrated compliance with international data-protection frameworks (HIPAA, GDPR, and emerging APAC standards).

Ensuring Equity and Access to AI-Enabled Care

AI-based cardiovascular tools risk widening healthcare disparities if access is limited to large, well-resourced institutions. MarketWatch health equity reports note that low-income and rural populations frequently lack access to advanced wearables, high-quality imaging, or broadband connectivity for remote monitoring. Frontiers and JAMA health policy analyses warn that algorithms trained predominantly on insured, urban patients may produce inequitable diagnostic recommendations when used in underserved communities. Achieving algorithmic equity requires subsidized access programs, regional dataset inclusion, and context-appropriate deployment strategies.

Regulatory Pathways, Clearances, and Global Approval Ecosystems

Regulatory agencies—including the FDA (USA), MFDS (Korea), EMA (EU), PMDA (Japan)—are increasingly publishing detailed frameworks for validating AI-driven cardiovascular tools. Multiple platforms have secured FDA clearance for arrhythmia detection, atrial fibrillation risk estimation, and ECG-based diagnostic support, illustrating a viable pathway to clinical deployment. Irhythm's Zio-based digital biomarkers, for example, underwent rigorous analytical and clinical validation before approval. Nevertheless, regulatory bodies emphasize that approval is not a guarantee of long-term safety, and continuous post-market evaluation is mandatory.

Post-Market Surveillance and Real-World Performance Monitoring

Continuous monitoring of real-world performance is essential because model degradation, population shift, and device variability can impair clinical reliability over time. MarketWatch analyses note that investors and healthcare systems now expect AI companies to implement post-deployment audit dashboards, drift detectors, and real-world evidence (RWE) frameworks. Irhythm and similar cardiac-technology firms use large post-market registries to track false alarms, detection delays, and demographic differences in performance. High-impact journals stress that robust post-market surveillance is essential to close the loop between algorithm development, validation, deployment, and iterative safety updates.

5. Recommendations for Clinical Integration & Future Research

Prioritize Prospective, Outcome-Oriented Trials

To ensure that AI-assisted cardiovascular tools deliver meaningful patient benefit, research should emphasize prospective, outcome-oriented trials rather than relying solely on retrospective AUC metrics. Randomized controlled trials (RCTs) or pragmatic studies measuring hard clinical

endpoints—such as stroke incidence, myocardial infarction, hospitalization rates, and mortality—provide definitive evidence of clinical utility. AHA journals have highlighted that retrospective performance often overestimates effectiveness in real-world scenarios, making prospective validation essential. Outcome-driven studies also facilitate assessment of cost-effectiveness, workflow integration, and clinician adoption.

Leverage Diverse, Federated Data for Training

AI models benefit from multi-institutional, heterogeneous datasets that capture variations in demographics, disease prevalence, and healthcare infrastructure. Federated learning frameworks, as described in MDPI publications, allow models to learn across distributed datasets without direct data sharing, preserving privacy and regulatory compliance while improving generalizability. Integrating such approaches reduces bias, minimizes overfitting to single-institution data, and strengthens the model's adaptability across geographic regions and healthcare settings.

Implement Human-in-the-Loop Workflows

Clinical AI should be deployed in a human-in-the-loop framework, where algorithms augment, rather than replace, clinician decision-making. Platforms discussed in irhythmtech.com exemplify workflows in which AI triages high-risk patients, flags abnormalities, and provides probabilistic recommendations while clinicians maintain final interpretive authority. Clear escalation pathways, feedback loops, and user-friendly interfaces are critical to reduce automation complacency and ensure safe integration into daily practice. Iterative clinician feedback also allows continuous model refinement.

Strengthen Regulatory Oversight and Post-Market Surveillance

Robust regulatory frameworks are vital to guarantee safe and effective AI deployment. Nature editorials emphasize the importance of standards for real-world performance monitoring, bias auditing, and ongoing certification post-approval. Regulatory bodies should require evidence of continuous model validation, detection of drift, and reporting of adverse events. Integration of real-world evidence registries and transparent audit logs ensures accountability and maintains patient trust in AI-assisted interventions.

Promote Equity and Inclusive Access

Equity must be a central consideration in AI deployment. Models trained and validated only in well-resourced settings risk perpetuating disparities. Nature publications recommend that AI tools undergo testing in low-resource and underrepresented populations, ensuring diagnostic accuracy, clinical effectiveness, and accessibility across socio-economic groups. Strategies include subsidized technology provision, regional dataset inclusion, and culturally adapted user interfaces to facilitate broad adoption without exacerbating health inequities.

Encourage Multidisciplinary Collaboration

Successful AI integration requires collaboration among clinicians, data scientists, engineers, ethicists, and policymakers. Multidisciplinary teams can identify clinical pain points, ensure algorithmic transparency, and establish operational protocols for adoption. Journals like AHA and Lancet Digital Health advocate for joint academic-industry initiatives that combine technical innovation with clinical insight, creating tools that are not only accurate but also actionable in routine care.

Foster Continuous Learning and Future Research Directions

Future research should focus on adaptive AI systems capable of learning from new data streams, including wearable sensors, imaging modalities, and electronic health records. Open-source frameworks, federated learning networks, and multi-center collaborations can accelerate innovation while maintaining safety. Longitudinal studies are particularly valuable for assessing long-term outcomes, cost-effectiveness, and patient-centered metrics. By combining rigorous trial design, diverse datasets, and clinician engagement, AI tools can transition from experimental prototypes to integral components of cardiovascular care.

Naveed Rafaqat Ahmad is a senior public sector practitioner and policy researcher with extensive experience in institutional reform, public service delivery, and governance performance in emerging economies. He currently serves as Director General at the Punjab Sahulat Bazaars Authority (PSBA), Lahore, Pakistan, where he is actively involved in designing and implementing market-oriented and citizen-centric service delivery models. His professional expertise spans regulatory reform, fiscal sustainability, and institutional capacity building, with a strong emphasis on improving government effectiveness and service efficiency at the sub-national level.

Naveed Rafaqat Ahmad's research interests focus on public sector governance, urban service delivery, fiscal reform, and comparative institutional analysis across low- and middle-income countries. His scholarly work employs internationally recognized datasets, including the Worldwide Governance Indicators (WGI), IMF fiscal indicators, and World Bank development metrics, to evaluate governance outcomes and reform effectiveness. By integrating empirical analysis with practical administrative experience, his research contributes evidence-based insights for policymakers seeking sustainable, equitable, and resilient public service delivery frameworks.

The article begins by analyzing the persistent structural weaknesses in public welfare systems, particularly in developing economies. These weaknesses include the dependence on recurring fiscal subsidies, weak enforcement of administered prices, and institutional arrangements lacking autonomy, which limit the efficiency of welfare mechanisms.

Finally, the article invites a broader reconsideration of how success is measured in welfare policy. Rather than focusing narrowly on budgetary outlays or beneficiary counts, the PSBA framework emphasizes metrics such as price differentials, operational efficiency, compliance rates, and institutional sustainability. These indicators capture both economic and governance dimensions of welfare performance, offering a more holistic evaluation framework. This shift in metrics has important implications for policy design and evaluation, as it aligns welfare success with long-term affordability, administrative discipline, and public trust rather than short-term political visibility.

Naveed Rafaqat Ahmad is a governance reform practitioner and policy researcher whose work focuses on digital government, regulatory governance, and the responsible adoption of emerging technologies in public administration. His research examines how artificial intelligence can improve government efficiency while maintaining accountability, transparency, and citizen trust. Ahmad particularly emphasizes risk-based regulatory frameworks that help governments classify AI systems according to their potential impact and apply appropriate oversight mechanisms. Through his work, he highlights the importance of human oversight, algorithmic transparency, data quality management, and institutional accountability in AI-enabled public sector systems. His contributions support policymakers in developing practical governance models that allow governments—especially in developing states—to benefit from AI innovation while protecting procedural fairness and democratic governance principles.

Summary

AI-assisted diagnostic tools show promising effectiveness for early detection of a range of cardiovascular conditions: high-performing ECG algorithms for arrhythmia and risk prediction, AI-supported CCTA interpretation for coronary disease, and wearable-AI systems that can provide lead time for decompensation. Several systems have progressed to regulatory clearance and early clinical deployment, delivering gains in sensitivity, reduced time-to-diagnosis, and workflow efficiency. Nevertheless, the true impact on patient outcomes requires prospective trials, rigorous real-world monitoring, and careful attention to bias, integration, and equitable access. When deployed thoughtfully—human-centred, transparently validated, and continuously audited—AI diagnostic tools can be powerful enablers of earlier detection and improved cardiovascular care.

References

Asselbergs, F. W., et al. (2021). Artificial intelligence in cardiology: the debate continues. European Heart Journal - Digital Health. OUP Academic

Ansari, Y., et al. (2023). Deep learning for ECG arrhythmia detection: survey and perspectives. Journal of Healthcare Engineering. PMC

Murat, F., et al. (2021). Review of deep learning–based atrial fibrillation detection using ECG. International Journal of Environmental Research and Public Health. MDPI

Mastrodicasa, D., et al. (2025). Use of AI in cardiac CT and MRI: a scientific statement. Radiology (multisociety statement). RSNA Publications

Betancur, J., et al. (2022). Deep learning myocardial perfusion imaging and CAD detection — comparative study. Journal of Nuclear Cardiology. healthcare-bulletin.co.uk

Hadida Barzilai, D., et al. (2025). Randomized controlled trials evaluating AI in cardiovascular care: systematic review. JACC: Advances. JACC

Yu, T., et al. (2025). Enhancing cardiac disease detection via fusion of machine learning and medical image analysis. Scientific Reports. Nature

Velandia, H., et al. (2025). Systematic review: AI-ECG applications for early detection of cardiovascular disease. Biosensors / MDPI. MDPI

Czerwinski, A., et al. (2025). Interpretable arrhythmia detection using deep learning ensembles and XAI. npj Digital Medicine. Nature

Wu, Z., et al. (2025). Deep learning and electrocardiography: systematic review of architectures and clinical tasks. BioMedical Engineering OnLine. SpringerLink

Tripathi, S., et al. (2025). Cardiothoracic imaging AI for cardiac diseases: imaging biomarkers and detection. Clinical Radiology / Elsevier. ScienceDirect

Marey, A., et al. (2025). From echocardiography to CT/MRI: AI diagnostic performance across modalities. PubMed Central (review). PMC

Jin, Y., et al. (2025). Explainable paroxysmal atrial fibrillation diagnosis using deep learning on ECG. Korean Journal of Internal Medicine. KJIM

Pushadapu, V. V., et al. (2025). Artificial Intelligence and Machine Learning: diagnostic devices for early CVD detection. Machine Learning in Healthcare. SpringerLink

Nakamura, T., et al. (2022). Artificial intelligence and cardiology: current status and future directions. Cardiology Journals / Elsevier. ScienceDirect

Nzeako, T. R., et al. (2025). Artificial intelligence in interventional cardiology: review of diagnostic and procedural roles. PMC Article. PMC

Gunjal, A., et al. (2025). A comprehensive survey of AI methods for improving CVD diagnosis. Journal of Biomedical Informatics / ScienceDirect. ScienceDirect

Tayyeb, M., et al. (2023). Deep learning approach for automatic cardiovascular disease prediction: model and evaluation. Computers in Biology and Medicine. ScienceDirect

(News / translational) Coverage of AI-ECG tools (Aire / EchoNext / wearable-AI studies) — reporting on large-scale ECG-trained models for early structural heart disease detection. The Guardian / Financial Times / NYPost summaries. The Guardian+2Financial Times+2

Comprehensive review: "Artificial intelligence in cardiovascular diagnostics" — review synthesizing diagnostic accuracy, clinical readiness, and challenges (bias, validation, regulation). PubMed Central review (2025). PMC

Ahmad, N. R. (2024). *Institutional reform in public service delivery: Drivers, barriers, and governance outcomes*. **Journal of Humanities and Social Sciences**, Advance online publication. https://doi.org/10.52152/jhs8rn12

Ahmad, N. R. (2025). *Urban water service delivery in emerging economies: Fiscal sustainability, cost recovery, and governance performance*. **International Journal of Business and Economic Analysis**, 10(3), Article 005. https://doi.org/10.24088/IJBEA-2025-103005

Irk, E. (2025). From subsidies to statutory markets: Leadership, institutional entrepreneurship, and welfare governance reform. Lex Localis – Journal of Local Self-Government, 23(S6), 9549–9566. https://doi.org/10.52152/s59sjh53

Ahmad, N. R. (2024). *AI-enabled public governance in developing states: Service delivery gains, accountability risks, and a practical risk-based regulatory model.* https://doi.org/10.52152/wja5db40